Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis

Trial Profile

A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2019

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Acronyms RA-BEYOND
  • Sponsors Eli Lilly and Company; Eli Lilly Japan
  • Most Recent Events

    • 15 Jun 2019 Results of pooled analysis from nine studies of Baricitinib treated rheumatoid arthritis patients presented at the 20th Annual Congress of the European League Against Rheumatism
    • 06 Jun 2019 According to an Eli Lilly media release, data from this trial will be presented at the upcoming Annual European Congress of Rheumatology (EULAR 2019) in Madrid from June 12-15, 2019.
    • 30 Apr 2019 Results assessing clinical outcomes in patients who changed treatment from adalimumab to baricitinib during a phase III programme (RA-BEAM and RA-BEYOND), were published in the Annals of the Rheumatic Diseases Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top